Smoking Cessation and Lung Function in Mild-to-Moderate Chronic Obstructive Pulmonary Disease

Scanlon, Paul D.; Connett, John E.; Waller, Lance A.; Altose, Murray D.; Bailey, William C.; Buist, A. Sonia; Tashkin, Donald P.

doi:10.1164/ajrccm.161.2.9901044

Cited by 627 publications

(249 citation statements)

References 16 publications

Supporting

Mentioning

223

Contrasting

Unclassified

Order By: Relevance

“…The groups listed in Table 1 also have a disproportionate burden of tobacco-related disease compared with a general population of smokers, especially substance abusers who smoke and smokers with HIV/AIDS or medical comorbidities (Crothers et al, 2005;Hurt et al, 1996;Scanlon et al, 2000;Turner et al, 2001;Twardella, Rothenbacher, Hahmann, Wusten, & Brenner, 2006;Wilson, 2006). Many of the groups in Table 1 have less access to effective treatments or are less likely to receive advice to quit from health care practitioners, especially smokers with low socioeconomic status (SES), mobility-impaired smokers, and Native American smokers (Connor, Cook, Herbert, Neal, & Williams, 2002;Murphy, Mahoney, Hyland, Higbee, & Cummings, 2005;Reed & Burns, 2008).…”

Section: Smoking Prevalencementioning

confidence: 99%

Smoking cessation: Next steps for special populations research and innovative treatments.

Borrelli

2010

Journal of Consulting and Clinical Psychology

View full text Add to dashboard Cite

Objective:The current introductory article provides the rationale for the special section on understudied smokers and innovative treatments. This article proposes a definition of "special populations" of smokers, outlines a priori criteria by which to judge whether an intervention should be adapted for these smokers, and delineates a process by which cultural adaptation of an intervention can be achieved. Next steps for innovative, theory-based treatments with special populations and with general populations of smokers are discussed. Method: Special populations of smokers are defined as having (a) Ͼ10% higher smoking prevalence than the general population of smokers, (b) disproportionate tobacco-related health disparities, (c) less access to treatments, and (d) a lack of prospective, longitudinal treatment trials. Results: Cultural adaptation of evidenced-based treatments (EBTs) for underserved smokers should be applied more widely, outside the bounds of race and ethnicity, but also judiciously, following several a priori criteria. Cultural adaptation may be justified if the target population differs from the general population in (a) rates and patterns of smoking, (b) burden of tobacco-related health diseases, (c) predictors of smoking behavior, (d) risk factors for treatment failure, (e) protective factors that facilitate quitting, (f) treatment engagement, (g) treatment response, and (h) perceived social validity of the EBT. Once these criteria are met, four phases of cultural adaptation of an EBT for the target population are proposed. Innovative treatments need to be developed that use novel channels and linkages between channels; test novel theories or build on mechanisms research to more accurately pinpoint targets of change; and increase consumer demand for EBTs. Conclusion: The process of cultural adaptation should be thoughtfully conducted with a priori definitions and criteria as well as standardized processes. Coupled with innovative, theory-based treatments, these considerations could help to jump-start stalled smoking cessation rates. Decreasing the prevalence of smoking will take a multitarget, multichannel, multimethod approach at different levels of social strata: individuals (i.e., address smoker heterogeneity, develop innovative treatments), groups (i.e., target populations with higher than average smoking prevalence; eradicate disparities in treatment access, engagement, and effectiveness), cultural/societal level (i.e., increase frequency and effectiveness of mass media campaigns, create greater consumer demand for evidenced-based treatments [EBTs]), health care systems and insurers (i.e., increase counseling and reimbursement, reduce out-of-pocket costs to smokers who want to quit), and government (i.e., increase taxation, expand smoke-free laws, increase funding of state quit lines).Although all of these factors are critical to jump-starting stalled smoking cessation rates, in January 2009 the Journal of Consulting and Clinical Psychology initiated a call for papers focusing on the first t...

show abstract

Section: Smoking Prevalencementioning

confidence: 99%

Smoking cessation: Next steps for special populations research and innovative treatments.

Borrelli

2010

Journal of Consulting and Clinical Psychology

View full text Add to dashboard Cite

show abstract

“…18 FEV 1 is also vulnerable to the impact of smoking and ambient air pollution. 23,24 Therefore, the fixed ration of FEV 1 /FEV 6 for diagnosis of COPD also should be interpreted in the context of the patient's risk factors, age, and symptoms. However, the merit of using a fixed cutoff value for the FEV 1 /FEV 6 instead of a reference equation to diagnose COPD is still highlighted by the COPD guidelines.…”

Section: Discussionmentioning

confidence: 99%

FEV₁/FEV₆in Primary Care Is a Reliable and Easy Method for the Diagnosis of COPD

et al. 2015

View full text Add to dashboard Cite

BACKGROUND: FEV 6 can be used as a convenient alternative to FVC. The aim of this study was to determine an alternative to the fixed cutoff points of FEV 1 /FVC <0.70 suitable for FEV 1 /FEV 6 in primary care. METHODS: Pulmonary function testing was conducted on volunteers recruited from 4 community centers in Xi'an, China, between July and August 2012. Participants underwent 3 FVC maneuvers. The maneuver with the best FEV 1 was retained. FVC, FEV 1 , and FEV 6 were measured by portable spirometer. The receiver operating characteristic curves that corresponded to the optimal combination of sensitivity and specificity for FEV 1 /FEV 6 were determined. A kappa test was used to compare the agreement between FEV 1 /FVC and FEV 1 /FEV 6 . The positive predictive value and negative predictive value were also calculated. RESULTS: A total of 767 volunteers participated in this study, of whom 297 were male and 470 were female. Considering FEV 1 /FVC <0.70 as the accepted standard for COPD, the area under the curve was 98% (P < .001), and the FEV 1 /FEV 6 cutoff, corresponding to the greatest sum of sensitivity and specificity, was 0.72. For the total population, the FEV 1 /FEV 6 sensitivity, specificity, positive predictive value, and negative predictive value were 96.9, 98.8, 95.8, and 99.2%, respectively. The agreement between the 2 cutoff points was excellent, and the kappa value was 0.954. CONCLUSIONS: FEV 1 /FEV 6 <0.72 can be used in primary care as a valid alternative to FEV 1 /FVC <0.70 as a fixed cutoff point for the detection of COPD in adults. This study suggests that FEV 1 /FEV 6 is an effective and well validated option that should be used in primary care to detect COPD, which is a rampant problem. Key words: COPD; forced expiratory volume in six seconds; pulmonary function testing; spirometry. [Respir Care 2016;61(3):349 -353.

show abstract

“…The greater alleviation of asthma symptoms among non-smokers is understandable, since smoking directly affects asthmatic symptoms [5,6] and the development of COPD [14]. Tobacco smoke can also affect symptoms by altering the response to inhaled corticosteroids [15].…”

Section: Discussionmentioning

confidence: 99%

What lies behind relief and worsening of asthma symptoms? A register-based study of adults with asthma and other chronic obstructive pulmonary diseases in Finland

Ikäheimo

Hartikainen

Tuuponen

et al. 2006

Primary Care Respiratory Journal

View full text Add to dashboard Cite

SummaryAims: To examine how subjects with relief or worsening of asthma symptoms differ in terms of gender, age, severity and duration of asthma, comorbidity, and difficulties with medication and daily life. Methods: A postal inquiry among a sample of 6000 adults with clinically diagnosed asthma and/or other chronic obstructive pulmonary diseases. Results: Relief of asthma symptoms over a 12-month period was associated with a recent asthma diagnosis, within five years, in both sexes. Lack of current smoking and lack of problems in using anti-asthmatic treatment were associated with a positive outcome in men, and mild asthma and living alone associated with a positive outcome in women. Severe and moderate asthma predicted worse symptoms in both sexes, as did other obstructive pulmonary diseases, living alone, and medication problems amongst men. Conclusions: Patients with asthma should be cared for comprehensively, requiring consideration of both clinical and psychosocial factors that can modify the course of the disease.

show abstract

Smoking Cessation and Lung Function in Mild-to-Moderate Chronic Obstructive Pulmonary Disease

Cited by 627 publications

References 16 publications

Smoking cessation: Next steps for special populations research and innovative treatments.

Smoking cessation: Next steps for special populations research and innovative treatments.

FEV₁/FEV₆in Primary Care Is a Reliable and Easy Method for the Diagnosis of COPD

What lies behind relief and worsening of asthma symptoms? A register-based study of adults with asthma and other chronic obstructive pulmonary diseases in Finland

Contact Info

Product

Resources

About

Smoking Cessation and Lung Function in Mild-to-Moderate Chronic Obstructive Pulmonary Disease

Cited by 627 publications

References 16 publications

Smoking cessation: Next steps for special populations research and innovative treatments.

Smoking cessation: Next steps for special populations research and innovative treatments.

FEV1/FEV6in Primary Care Is a Reliable and Easy Method for the Diagnosis of COPD

What lies behind relief and worsening of asthma symptoms? A register-based study of adults with asthma and other chronic obstructive pulmonary diseases in Finland

Contact Info

Product

Resources

About

FEV₁/FEV₆in Primary Care Is a Reliable and Easy Method for the Diagnosis of COPD